Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula

StatusTerminated
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: No enough subjects within the recruitment period Show 5 more changesShow less
    • Final enrollment: 7 participants (planned 40)
    • Study completion date changed from estimate of Aug 18, 2026 to Aug 18, 2025
    • Eligibility criteria expanded, about 13 words
    • Site details revised at 2 of 2 sites
    • Publications: details revised at 3 of 3 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Aug 19, 2024 to Sep 11, 2024
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.
Trial Details
NCT Number NCT06560385
Lead Sponsor GenieBiome Limited
Conditions
(from sponsor)		 Breast Cancer, Hair Loss
Related terms Alopecia, Breast Neoplasms
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov